WO2000046203A3 - G-protein coupled heptahelical receptor binding compounds and methods of use thereof - Google Patents

G-protein coupled heptahelical receptor binding compounds and methods of use thereof Download PDF

Info

Publication number
WO2000046203A3
WO2000046203A3 PCT/US2000/003042 US0003042W WO0046203A3 WO 2000046203 A3 WO2000046203 A3 WO 2000046203A3 US 0003042 W US0003042 W US 0003042W WO 0046203 A3 WO0046203 A3 WO 0046203A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein coupled
methods
binding compounds
receptor binding
coupled heptahelical
Prior art date
Application number
PCT/US2000/003042
Other languages
French (fr)
Other versions
WO2000046203A2 (en
Inventor
Kazumi Shiosaki
Paul Fleming
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Priority to EP00907184A priority Critical patent/EP1150955A2/en
Priority to CA002362401A priority patent/CA2362401A1/en
Priority to AU28719/00A priority patent/AU2871900A/en
Priority to MXPA01007957A priority patent/MXPA01007957A/en
Publication of WO2000046203A2 publication Critical patent/WO2000046203A2/en
Publication of WO2000046203A3 publication Critical patent/WO2000046203A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/75—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

G-protein coupled heptahelical binding compounds are described, e.g. compounds of the formula (I): J-M wherein J is an aromatic moiety and M is a G-protein coupled heptahelical receptor pocket interacting moiety. The compounds of the invention can be used to treat chemokine mediated disorders, e.g. neurological, immunological, inflammatory and cancer related disorders.
PCT/US2000/003042 1999-02-04 2000-02-03 G-protein coupled heptahelical receptor binding compounds and methods of use thereof WO2000046203A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00907184A EP1150955A2 (en) 1999-02-04 2000-02-03 G-protein coupled heptahelical receptor binding compounds and methods of use thereof
CA002362401A CA2362401A1 (en) 1999-02-04 2000-02-03 G-protein coupled heptahelical receptor binding compounds and methods of use thereof
AU28719/00A AU2871900A (en) 1999-02-04 2000-02-03 G-protein coupled heptahelical receptor binding compounds and methods of use thereof
MXPA01007957A MXPA01007957A (en) 1999-02-04 2000-02-03 G-protein coupled heptahelical receptor binding compounds and methods of use thereof.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11889399P 1999-02-04 1999-02-04
US60/118,893 1999-02-04

Publications (2)

Publication Number Publication Date
WO2000046203A2 WO2000046203A2 (en) 2000-08-10
WO2000046203A3 true WO2000046203A3 (en) 2001-03-01

Family

ID=22381391

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/003042 WO2000046203A2 (en) 1999-02-04 2000-02-03 G-protein coupled heptahelical receptor binding compounds and methods of use thereof

Country Status (5)

Country Link
EP (1) EP1150955A2 (en)
AU (1) AU2871900A (en)
CA (1) CA2362401A1 (en)
MX (1) MXPA01007957A (en)
WO (1) WO2000046203A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012462B2 (en) 2008-05-21 2015-04-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
JP7312227B2 (en) 2015-12-24 2023-07-20 協和キリン株式会社 α, β unsaturated amide compounds

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
CN101596191B (en) 2001-01-26 2011-06-15 中外制药株式会社 Method for treatment of disease using malonyl-coa decarboxylase inhibitor
ES2284817T3 (en) 2001-01-26 2007-11-16 Chugai Seiyaku Kabushiki Kaisha PROCEDURES FOR THE TREATMENT OF DISEASES WITH INHIBITORS OF MALONIL COA DESCARBOXYLASE.
ES2274005T3 (en) 2001-01-26 2007-05-16 Chugai Seiyaku Kabushiki Kaisha MALONYL-COA DECARBOXYLASE INHIBITORS USED AS METABOLIC MODULATORS.
US7709510B2 (en) 2001-02-20 2010-05-04 Chugai Seiyaku Kabushiki Kaisha Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
BR0207408A (en) 2001-02-20 2004-02-25 Chugai Pharmaceutical Co Ltd Azoles as malonyl coa decarboxylase inhibitors useful as metabolic modulators
DE60324104D1 (en) * 2002-01-30 2008-11-27 Amgen Inc Arylsulfonamidobenzylverbindungen
WO2003063796A2 (en) 2002-01-30 2003-08-07 Tularik Inc. Heterocyclic arylsulfonamidobenzylic compounds
US7205307B2 (en) 2002-02-14 2007-04-17 Icagen, Inc. Pyrimidines as novel openers of potassium ion channels
JP4727579B2 (en) 2003-08-01 2011-07-20 中外製薬株式会社 Cyanamide compounds useful as malonyl-CoA decarboxylase inhibitors
ES2353306T3 (en) 2003-08-01 2011-03-01 Chugai Seiyaku Kabushiki Kaisha USEFUL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MALONIL-COA-DESCARBOXYLASE.
EP1658071B1 (en) 2003-08-01 2008-09-10 Chugai Seiyaku Kabushiki Kaisha Cyanoguanidine-based azole compounds useful as malonyl-coa decarboxylase inhibitors
ATE400272T1 (en) 2003-08-01 2008-07-15 Chugai Pharmaceutical Co Ltd PIPERIDINE COMPOUNDS AS MALONYL-COA DECARBOXYLASE INHIBITORS
US7037927B2 (en) * 2003-10-16 2006-05-02 Abbott Laboratories Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor
US8188277B2 (en) 2004-08-06 2012-05-29 Otsuka Pharmaceutical Co., Ltd. Aromatic compounds for suppressing the generation of collagen
ATE462697T1 (en) * 2004-08-12 2010-04-15 Amgen Inc BISARYL SULFONAMIDES
JP4980928B2 (en) * 2004-12-24 2012-07-18 プロシディオン・リミテッド G protein-coupled receptor (GPR116) agonist and use thereof for the treatment of obesity and diabetes
EP1945208A4 (en) * 2005-10-06 2011-08-03 Univ Massachusetts Composition and synthesis of new reagents for inhibition of hiv replication
EP1957073B1 (en) 2005-12-05 2014-04-23 Otsuka Pharmaceutical Co., Ltd. Medicinal drug
US8030487B2 (en) * 2006-07-07 2011-10-04 Targegen, Inc. 2-amino—5-substituted pyrimidine inhibitors
UA95978C2 (en) 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Stat3/5 activation inhibitor
MX2009008798A (en) * 2007-02-22 2009-08-24 Syngenta Participations Ag Iminipyridine derivatives and their uses as microbiocides.
JP2009185020A (en) * 2008-01-11 2009-08-20 Ishihara Sangyo Kaisha Ltd Pyridylamidine derivative or salt thereof, and agricultural or horticultural fungicide containing the same as active ingredient
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
EP3549934A1 (en) 2008-06-27 2019-10-09 Celgene CAR LLC Heteroaryl compounds and uses thereof
KR101705158B1 (en) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Egfr inhibitors and methods of treating diseases
US8962656B2 (en) * 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
BR112013003388A2 (en) 2010-08-10 2016-07-12 Celgene Avilomics Res Inc besylate salt of a btk inhibitor
WO2012061303A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
JP5957460B2 (en) 2010-11-01 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド Heterocyclic compounds or uses thereof
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
US8796255B2 (en) 2010-11-10 2014-08-05 Celgene Avilomics Research, Inc Mutant-selective EGFR inhibitors and uses thereof
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
EA201391626A1 (en) 2011-05-04 2014-03-31 Ариад Фармасьютикалз, Инк. COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-STIMULATED CANCER TYPES
AR088570A1 (en) 2011-10-28 2014-06-18 Celgene Avilomics Res Inc METHODS TO TREAT AN ILLNESS OR DISORDER RELATED TO BRUTON TYROSINE KINASE
WO2013138495A1 (en) 2012-03-15 2013-09-19 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
CN104284584B (en) 2012-03-15 2019-06-04 西建卡尔有限责任公司 The salt of epidermal growth factor receptor kinase inhibitor
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
ITMI20120785A1 (en) * 2012-05-09 2013-11-10 Fond Italiana Sclerosi M Ultipla Fism Onlu MODULATORS OF THE GPR17 RECEPTOR
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9145387B2 (en) 2013-02-08 2015-09-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
AP2015008721A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
EA201992707A1 (en) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP3179858B1 (en) 2014-08-13 2019-05-15 Celgene Car Llc Forms and compositions of an erk inhibitor
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
CN114149341B (en) * 2021-12-08 2023-07-21 中国药科大学 Aryloxy cyclohexyl amide AMPK agonist, and preparation method and medical application thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3804346A1 (en) * 1988-02-12 1989-08-24 Boehringer Mannheim Gmbh tert-Butylphenylpyridyl amides, process for their preparation, and medicaments containing these compounds
EP0487252A1 (en) * 1990-11-19 1992-05-27 Zeneca Limited Quinoline and 1,5-Naphthyridine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
WO1997005877A1 (en) * 1995-08-10 1997-02-20 Merck & Co., Inc. 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
WO1999024404A1 (en) * 1997-11-07 1999-05-20 Amgen Inc. Substituted pyridine compounds as anti-inflammatory agents
WO1999048871A1 (en) * 1998-03-25 1999-09-30 Otsuka Pharmaceutical Co., Ltd. Pyridine derivative and pharmaceutical containing the same
WO2000056729A1 (en) * 1999-03-24 2000-09-28 Anormed Inc. Chemokine recpetor binding heterocyclic compounds

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3804346A1 (en) * 1988-02-12 1989-08-24 Boehringer Mannheim Gmbh tert-Butylphenylpyridyl amides, process for their preparation, and medicaments containing these compounds
EP0487252A1 (en) * 1990-11-19 1992-05-27 Zeneca Limited Quinoline and 1,5-Naphthyridine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
WO1997005877A1 (en) * 1995-08-10 1997-02-20 Merck & Co., Inc. 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
WO1999024404A1 (en) * 1997-11-07 1999-05-20 Amgen Inc. Substituted pyridine compounds as anti-inflammatory agents
WO1999048871A1 (en) * 1998-03-25 1999-09-30 Otsuka Pharmaceutical Co., Ltd. Pyridine derivative and pharmaceutical containing the same
WO2000056729A1 (en) * 1999-03-24 2000-09-28 Anormed Inc. Chemokine recpetor binding heterocyclic compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BALCELLS, MERCE ET AL: "Synthesis of Phenoxyphenyl Pyridine and Pyrazine Carboxamides. Activity against Cydia pomonella (L.) Eggs", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY., vol. 48, no. 1, January 2000 (2000-01-01), AMERICAN CHEMICAL SOCIETY. WASHINGTON., US, pages 83 - 87, XP002154583, ISSN: 0021-8561 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012462B2 (en) 2008-05-21 2015-04-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
JP7312227B2 (en) 2015-12-24 2023-07-20 協和キリン株式会社 α, β unsaturated amide compounds

Also Published As

Publication number Publication date
AU2871900A (en) 2000-08-25
CA2362401A1 (en) 2000-08-10
MXPA01007957A (en) 2002-07-30
WO2000046203A2 (en) 2000-08-10
EP1150955A2 (en) 2001-11-07

Similar Documents

Publication Publication Date Title
WO2000046203A3 (en) G-protein coupled heptahelical receptor binding compounds and methods of use thereof
WO2001010842A3 (en) Melanocortin-4 receptor binding compounds and methods of use thereof
EP1363890A4 (en) Melanocortin-4 receptor binding compounds and methods of use thereof
HK1071127A1 (en) A2b adenosine receptor antagonists a2b
AU2001261640A1 (en) Adaptive stimulator for relief of symptoms of neurological disorders
AU3041100A (en) Binding of antibody fragments to solid supports
WO2002072548A3 (en) Heterocyclic compounds and their use as histamine h4 ligands.
AU4775900A (en) Muscle contraction assist device
HK1043985A1 (en) Chemokine receptor binding heterocyclic compounds
WO2002022600A3 (en) Chemokine receptor binding heterocyclic compounds
WO2001055106A3 (en) Novel melanocortin receptor agonists and antagonists
AU2935200A (en) Compounds for the treatment of obesity
WO1999002497A3 (en) Pyridine derivatives
WO1999033859A3 (en) Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
WO2002032874A8 (en) Substituted heterocyclic compounds for treating multidrug resistance
WO2003027061A3 (en) Muscarinic agonists
AU6182000A (en) Remedies for neurogenic pains
ZA200107906B (en) Anti-idiotypic antibodies against antibodies which inhibit the binding of immunoglobuline to its high affinity receptor.
AU4453300A (en) Assessment of gastric emptying disorders
AU4856600A (en) Use of agonists or antagonists of the 5-ht7 receptor to treat disorders of the bladder
AR020327A1 (en) USE OF A THERAPEUTICALLY EFFECTIVE AMOUNT OF (-) NORCISAPRIDA, OR A PHARMACOLOGICALLY ACCEPTABLE SALT OF THE SAME, SUBSTANTIALLY FREE FROM ITS (+) STEREOISOMERO, FOR THE PREPARATION OF MEDICINES.
AU2454700A (en) Improved foldaway umbrella
AU7652400A (en) Novel combination for the treatment of sexual dysfunction
WO2002032429A3 (en) Use of inhibitors of progesterone receptor for treating cancer
WO2002057313A8 (en) Receptor-binding compounds and methods for identifying them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/007957

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2362401

Country of ref document: CA

Kind code of ref document: A

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000907184

Country of ref document: EP

Ref document number: 28719/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000907184

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000907184

Country of ref document: EP